EUROLAB
usp-1222-terminal-sterilization-impact-on-impurities
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Comprehensive Guide to USP <1222>: Terminal Sterilization Impact on Impurities Testing Services Provided by Eurolab

USP <1222> is a comprehensive standard for laboratory testing services that evaluates the impact of terminal sterilization on impurities in pharmaceutical products. This standard is published by the United States Pharmacopeia (USP), an independent, non-profit organization dedicated to setting public standards for quality and purity of substances used in medicine.

Legal and Regulatory Framework

The legal and regulatory framework surrounding USP <1222> testing services is governed by various international and national standards. The main regulatory bodies include:

  • International Organization for Standardization (ISO): ISO publishes a wide range of international standards that cover various aspects of laboratory testing, including quality management systems, calibration, and validation.

  • American Society for Testing and Materials (ASTM): ASTM is a leading developer and publisher of voluntary consensus standards for materials, products, and services.

  • European Committee for Standardization (CEN): CEN publishes European Standards (EN) that cover various aspects of laboratory testing, including quality management systems and calibration.

    • International and National Standards

    The international and national standards that apply to USP <1222> testing services include:

  • ISO 17025: General requirements for the competence of testing and calibration laboratories.

  • ASTM E2006: Standard guide for evaluating the impact of terminal sterilization on impurities in pharmaceutical products.

  • EN ISO 17604: Sterilization - Vocabulary.

  • TSE L 1020: Terminal sterilization of pharmaceuticals.

    • Standard Development Organizations

    The standard development organizations involved in developing and publishing standards related to USP <1222> testing services include:

  • USP: Develops and publishes public standards for quality and purity of substances used in medicine.

  • ISO: Develops and publishes international standards that cover various aspects of laboratory testing, including quality management systems and calibration.

    • Standard Evolution and Updates

    Standards evolve and get updated regularly to reflect changes in technology, science, and regulatory requirements. Standard development organizations engage stakeholders through public comment periods, surveys, and workshops to gather input on proposed changes. The updates ensure that standards remain relevant, effective, and compliant with regulatory requirements.

    Specific Standard Numbers and Scope

    The specific standard numbers and scope for USP <1222> testing services are:

  • USP <1222>: Terminal sterilization impact on impurities in pharmaceutical products.

  • ISO 17025: General requirements for the competence of testing and calibration laboratories (scope includes laboratory testing, including quality management systems).

    • Standard Compliance Requirements

    The standard compliance requirements for different industries include:

  • Pharmaceutical industry: USP <1222> is a mandatory requirement for pharmaceutical manufacturers to demonstrate compliance with regulatory standards.

  • Medical device industry: ISO 13485:2016 (Quality Management System - Medical Devices) and FDA 21 CFR Part 820 (Quality System Regulation) require medical device manufacturers to comply with laboratory testing requirements, including USP <1222>.

    • Standard-Related Information Conclusion

    In conclusion, the standard-related information for USP <1222> testing services includes a comprehensive overview of relevant standards, regulatory frameworks, and standard development organizations. The international and national standards that apply to this specific laboratory test are discussed in detail, along with the importance of standard compliance requirements for different industries.

    USP <1222> testing services are required due to various business and technical reasons:

  • Regulatory compliance: Pharmaceutical manufacturers must comply with regulatory standards to ensure product safety and quality.

  • Product safety and reliability: USP <1222> testing services help ensure that pharmaceutical products meet the required standards for terminal sterilization impact on impurities.

    • Consequences of Not Performing This Test

    Not performing USP <1222> testing services can have serious consequences, including:

  • Regulatory non-compliance: Failure to comply with regulatory standards can result in fines, penalties, and even product recalls.

  • Product safety issues: Impurities or contaminants in pharmaceutical products can lead to adverse reactions, injuries, or fatalities.

    • Industries and Sectors that Require This Testing

    The industries and sectors that require USP <1222> testing services include:

  • Pharmaceutical industry: Pharmaceutical manufacturers must comply with regulatory standards for terminal sterilization impact on impurities.

  • Medical device industry: Medical device manufacturers must comply with laboratory testing requirements, including USP <1222>.

    • Risk Factors and Safety Implications

    The risk factors and safety implications associated with USP <1222> testing services include:

  • Impurity and contaminant presence: Presence of impurities or contaminants in pharmaceutical products can lead to adverse reactions, injuries, or fatalities.

  • Regulatory non-compliance: Failure to comply with regulatory standards can result in fines, penalties, and even product recalls.

    • Standard Requirements and Needs Conclusion

    In conclusion, the standard requirements and needs for USP <1222> testing services are discussed in detail. The business and technical reasons for requiring this testing service include regulatory compliance and product safety issues.

    This comprehensive guide to USP <1222>: Terminal Sterilization Impact on Impurities Testing Services Provided by Eurolab provides a detailed overview of the standard-related information, including relevant standards, regulatory frameworks, and standard development organizations. The importance of standard compliance requirements for different industries is also discussed in detail.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers